MedinCell (Group)

https://www.medincell.com

LinkedIn: https://www.linkedin.com/company/medincell

Medincell is a clinical- and commercial-stage biopharmaceutical licensing company developing long-acting injectable drugs in many therapeutic areas. Our innovative treatments aim to guarantee compliance with medical prescriptions, to improve the effectiveness and accessibility of medicines, and to reduce their environmental footprint. They combine active pharmaceutical ingredients with our proprietary BEPO® technology which controls the delivery of a drug at a therapeutic level for several days, weeks or months from the subcutaneous or local injection of a simple deposit of a few millimeters, entirely bioresorbable. The first treatment based on BEPO® technology, intended for the treatment of schizophrenia, was approved by the FDA in April 2023, and is now distributed in the United States by Teva under the name UZEDY® (BEPO® technology is licensed to Teva under the name SteadyTeq™). We collaborate with leading pharmaceutical companies and foundations to improve global health through new treatment options. Based in Montpellier, Medincell currently employs more than 140 people representing more than 25 different nationalities. *

	Start	2014-01-26 existent
	Industry	BEPO® technology
	Industry 2	drug delivery technology (drug formulation technology)
	Person	Douat, Christophe (MedinCell 201810 Board Chairman)
	Person 2	Arango, Jaime (MedinCell 202005 CFO)

	Region	Montpellier
	Country	France
	Street	3 rue des Frères Lumière
	City	34830 Jacou
		Address record changed: 2024-01-05

Basic data	Employees	D: 101 to 500 (2019-11-28)

		* Document for »About Section«: MedinCell S.A.. (4/16/24). "Press Release: Medincell Enters into Strategic Co-development and Licensing Agreement with AbbVie to Develop Next-generation Long-acting Injectable Therapies". Montpellier.

		Record changed: 2024-04-18